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Abstract
To address the need to study frozen clinical specimens using next-generation RNA, DNA,
chromatin immunoprecipitation (ChIP) sequencing and protein analyses, we developed a bio-
bank work flow to prospectively collect biospecimens from patients with renal cell carcinoma
(RCC). We describe our standard operating procedures and work flow to annotate pathologic
results and clinical outcomes. We report quality control outcomes and nucleic acid yields of
our RCC submissions (N=16) to The Cancer Genome Atlas (TCGA) project, as well as newer
discovery platforms, by describing mass spectrometry analysis of albumin oxidation in plasma
and 6 ChIP sequencing libraries generated from nephrectomy specimens after histone H3
lysine 36 trimethylation (H3K36me3) immunoprecipitation. From June 1, 2010, through Janu-
ary 1, 2013, we enrolled 328 patients with RCC. Our mean (SD) TCGARNA integrity numbers
(RINs) were 8.1 (0.8) for papillary RCC, with a 12.5% overall rate of sample disqualification for
RIN <7. Banked plasma had significantly less albumin oxidation (by mass spectrometry anal-
ysis) than plasma kept at 25°C (P<.001). For ChIP sequencing, the FastQC score for average
read quality was at least 30 for 91% to 95% of paired-end reads. In parallel, we analyzed fro-
zen tissue by RNA sequencing; after genome alignment, only 0.2% to 0.4% of total reads
failed the default quality check steps of Bowtie2, which was comparable to the disqualification
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ratio (0.1%) of the 786-O RCC cell line that was prepared under optimal RNA isolation condi-
tions. The overall correlation coefficients for gene expression between Mayo Clinic vs TCGA
tissues ranged from 0.75 to 0.82. These data support the generation of high-quality nucleic
acids for genomic analyses from banked RCC. Importantly, the protocol does not interfere
with routine clinical care. Collections over defined time points during disease treatment further
enhance collaborative efforts to integrate genomic information with outcomes.
Introduction
To support medical research, institutional biobanking efforts have encompassed archived for-
malin-fixed, paraffin-embedded (FFPE) tissue blocks, frozen tissues, peripheral blood, ques-
tionnaires, and medical records [1–4]. Genitourinary diseases are heterogeneous and range
from benign to malignant conditions [5,6]. The construction of a biobank encompassing both
benign and malignant genitourinary diseases may yield clues regarding molecular progression
of disease. In 2010, Mayo Clinic (Scottsdale, Arizona) initiated the Multidisciplinary Genitouri-
nary Diseases Biospecimen Bank to prospectively collect biospecimens from patients with geni-
tourinary diseases and to support health-related research. Herein, we report our experience
with frozen banking protocols for renal cell carcinoma (RCC) biospecimens that are compati-
ble with standard clinical practices.
The Cancer Genome Atlas (TCGA) Research Network has analyzed the DNA, RNA, and pro-
tein from various human tumors to generate molecular profiles, identify recurrent molecular
aberrations, and create public data portals to support medical research [7–11]. Currently, TCGA
integrates data fromDNAmethylation at CpG islands, microarray-based measurement of copy
number, whole-exome sequencing, RNA sequencing, and reverse-phase protein arrays. The
development of next-generation DNA, RNA, chromatin immunoprecipitation (ChIP) sequenc-
ing, and high-throughput protein analyses provides an opportunity for institutions to character-
ize genomic, transcriptomic, and proteomic alterations. However, the application of established
and emerging platforms for molecular analysis depends on well-annotated and high-quality bios-
pecimens. Furthermore, these platforms may necessitate large quantities of frozen biospecimens,
requiring standard operating procedures to be in place at the time of tissue collection.
To address an unmet need for banked clinical specimens suitable for high-throughput geno-
mic analysis, we developed a protocol to collect frozen tissue specimens, blood, and urine from
patients affected by RCC through longitudinal biospecimen collection during follow-up
appointments. We describe our standard operating procedures, work flow, and research coor-
dinator efforts, as well as our quality assessment of biospecimens submitted to TCGA from a
single institution. We also assessed the albumin oxidation in banked plasma, a surrogate of
plasma quality. It is unknown whether banked specimens collected under routine clinical care
are compatible with emerging discovery platforms such as ChIP sequencing. Herein, we dem-
onstrate that our biobanking protocol is compatible with multiple platforms, including DNA,
RNA, and ChIP sequencing, as well as mass spectrometry (MS) analysis.
Materials and Methods
Patient Eligibility and Recruitment
Patients eligible for enrollment were those seen at Mayo Clinic (Scottsdale, Arizona) who were
18 years old, able to provide informed consent, and undergoing evaluation for genitourinary
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diseases (kidney, urothelial, prostate, testicular, and penile malignancies or benign prostatic
hyperplasia or nephrolithiasis). Patients were contacted during routine clinical visits or in pre-
operative settings within Mayo Clinic departments and divisions, including urology, radiation
oncology, pathology, and medical oncology. Patients were excluded if they declined to partici-
pate or if the banking of their biospecimens would compromise the availability of tissue for
diagnosis and standard clinical care. The protocol for collecting biospecimens was approved by
the Mayo Clinic Institutional Review Board. The current informed consent form (S1 File),
which was updated in 2012, was approved by the Mayo Clinic Institutional Review Board (pro-
tocol no. 08–000980). Patients were enrolled from June 1, 2010, through January 1, 2013.
Patients provided written consent and the signed consent form was scanned into the electronic
medical record. Patients also received a copy of the signed consent form. This consent proce-
dure was approved by the Mayo Clinic Institutional Review Board.
Blood and Urine Collection
Blood and urine specimens are collected from patients preoperatively, postoperatively, and
during systemic treatments (every 3 months) for routine clinical care. The blood and urine are
transferred from the phlebotomist to the laboratory processing area within 30 minutes of col-
lection. Blood is collected in BD Vacutainer tubes (red top, Fisher Scientific 02-685-112, no
anticoagulants; lavender top, Fisher Scientific 02-657-32, K2 EDTA). Contents of red-top tubes
are allowed to clot for 10 to 30 minutes, then centrifuged at 1,882 relative centrifugal force
(RCF) for 10 minutes, and serum is transferred into 3×1.8-mL Nunc cryovials (Fisher Scientific
12565167N). Lavender-top tubes are centrifuged at 1,882 RCF in a refrigerated centrifuge;
plasma is then divided and placed into 3×1.8-mL Nunc cryovials (Fisher Scientific
12565167N); the remaining buffy coat is separated into 3×1.8-mL Nunc cryovials (Fisher Sci-
entific 12565167N). This protocol yields approximately 4.5 mL of plasma, serum, and buffy
coat per collection visit. Samples are stored at −80°C.
For urine collections, 2 mL of urine is divided into 2 cryovials for storage; the remaining
urine is centrifuged at 1,882 RCF for 5 minutes in a Hycor KOVA (Fisher Scientific VT87139)
tube in a refrigerated centrifuge. The supernatant is removed and the pellet resuspended in 1
mL of urine and stored in a cryovial. Centrifuged samples are stored at −80°C.
Tissue Collection
Surgical specimens are handled according to standards of clinical care. The specimens are
delivered directly from the operating room to the pathology department. After immediate mac-
roscopic review, the pathologist decides whether adequate tissue is available for banking. The
time from the start of warm ischemia to freezing can be as short as 10 minutes but as long as
110 minutes. The mean warm-ischemia time (ligation of blood flow) to freezing was 45.8 min-
utes. The warm-ischemia time is influenced by factors such as partial vs radical nephrectomy
or an open vs minimally invasive approach. The tumor sample (and a sample of uninvolved tis-
sue, if available) are macrodissected from the surgical specimen. Each sample is bisected, with
1 FFPE half as a mirror image representing the frozen biobank sample. The mirror-image
FFPE sample is used as one of the clinical diagnostic slides. The biobank samples are immedi-
ately frozen in 7-mL polycarbonate tubes (Sarstedt 71.9923.610) in a −90°C bath of Novec engi-
neered fluid (3M HFE-7000) cooled in a HistoChill freezing bath (SP Scientific HC80A0). No
embedding medium or preservative is added to frozen tissue. Tumor cellularity of the FFPE
mirror image is assessed by a pathologist and reported as part of the standard-of-care pathol-
ogy synoptic report.
Multidisciplinary Renal Cell Carcinomas Biobank
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Biospecimen Storage
Unique identification numbers are assigned to each individual container with bar code labels.
Biospecimens are stored in a Brooks BioStore −80°C Automated Sample Storage System
(Brooks Automation Inc). Samples can be retrieved manually or robotically.
Biobank Research Electronic Data Capture Database
A coded and secure Research Electronic Data Capture (REDCap) database was constructed
with pertinent clinical information and database identifiers. Biospecimens are tracked by
unique identification numbers assigned by the Research and Laboratory Information Manage-
ment System (RLIMS). Pertinent pre-, peri-, and postoperative clinical variables (procedures,
complications, and surgical outcomes) are annotated and linked to biospecimen data. In onco-
logic cases, we also annotate progression, survival, and treatment outcomes from the patient
medical record. Clinical follow-up is maintained by data coordinators for matched blood,
urine, and tissue (primary nephrectomies, biopsies, and metastectomies).
TCGA Papillary RCC Sample Submission
For papillary RCC solicited by TCGA (KIRP cases), a genitourinary pathologist (M.L.S.)
reviewed the diagnostic slide representing the frozen tumor. Specimens were selected only if
they met the standard TCGA biospecimen criteria with a corresponding buffy coat (for germ-
line DNA analysis). The minimum DNA, RNA, and germline DNA yield required was 6.9 μg,
5.15 μg, and 4.9 μg, respectively. For reverse-phase protein array analysis, at least 10 mg of fro-
zen tumor was required. Standard TCGA criteria included: 1) tumor sample composed pre-
dominantly of histologically viable-appearing tumor cells with60% tumor nuclei; 2)20%
necrosis of sample volume; and 3) tumor weight100 mg. The Mayo Clinic Institutional
Review Board protocol was subsequently modified to reflect the shipment of samples to
TCGA’s Biospecimen Core Resource (The Research Institute, Nationwide Children’s Hospital,
Columbus, Ohio). Prior to shipping, protected health information was removed from all mate-
rials (specimen containers, diagnostic slides, pathology reports). The top slide submitted for
review was the diagnostic slide cut from the bisected tumor, representing both the frozen
tumor and the FFPE tumor. The initial enrollment, case quality control, other malignancy, and
follow-up forms were completed by data coordinators using clinicopathologic variables entered
from the REDCap database. Prism (v6.02; GraphPad Software, Inc [commercial software]) was
used to generate scatter plots and statistics.
Analysis of Albumin and Apolipoprotein A-I Oxidation
Albumin S-cysteinylation and apolipoprotein A-I (apoA-I) methionine oxidation were ana-
lyzed as described in detail elsewhere [12]. Briefly, samples were thawed, mixed, and then cen-
trifuged to sediment particulates. One-half microliter was removed and diluted 1,000-fold in
0.1% (v/v) trifluoroacetic acid. Five microliters of this solution were injected without delay
onto a liquid chromatography—electrospray ionization—mass spectrometry instrument (Eksi-
gent nanoLC1D connected to a Bruker MicrOTOF-Q operating in time-of-flight only mode)
equipped with a protein CapTrap (Optimize Technologies) rather than a conventional column.
After flushing small molecules to waste for 3 minutes, albumin and apoA-I were eluted into the
mass spectrometer by increasing the acetonitrile concentration over the CapTrap.
Mass spectra containing protein charge envelopes were averaged across approximately 1
minute and then charge-deconvoluted with DataAnalysis (v3.4; Bruker Corp [commercial
software]) to a mass range of 1,000 Da on either side of any identified peak. Baseline values
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were subtracted from deconvoluted spectra and all peak heights were calculated. Tabulated
MS peak heights were exported to a spreadsheet for further calculation. The fractional abun-
dance of S-cysteinylated (oxidized) albumin was determined by dividing the height of the MS
peak representing S-cysteinylated albumin by the sum of the peak heights for native and S-
cysteinylated albumin. ApoA-I methionine oxidation was calculated in an analogous fashion.
No MS peaks representing apoA-I with 2 or 3 oxides were detected; however, if they had been,
these peaks would have been weighted to calculate total weighted oxidation, as described else-
where [12].
ChIP Sequencing
Nephrectomy samples underwent gross macrodissection to ensure that they contained>60%
to 70% tumor, with verification by a mirror slide stained with hematoxylin-eosin. Frozen tis-
sues were divided into 50-mg aliquots and stored in 1.5-mL centrifuge tubes at −70°C. Frozen
tissues were homogenized on ice for 15–30 seconds in 500 μL 1× phosphate-buffered saline
using a tissue grinder (AgileGrinder; ACTGene, Inc). Tissue homogenates were cross-linked
using formaldehyde (final concentration, 1%) for 10 minutes; reactions were quenched with
125 mM glycine for 5 minutes at room temperature and washed once with Tris-buffered saline.
Pellets were resuspended in cell lysis buffer (10 mM Tris-HCl, pH 7.5; 10 mM NaCl; 0.5% NP-
40) and incubated on ice for 10 minutes. Lysates were divided into 2 aliquots and washed with
micrococcal nuclease (MNase) digestion buffer (20 mM Tris-HCl, pH 7.5; 15 mM NaCl; 60
mM KCl; 1 mM CaCl2). After resuspending in 500 μL MNase digestion buffer containing a
proteinase inhibitor cocktail (no. 37491; Active Motif Corp), lysates were incubated in the pres-
ence of 1,000 gel units of MNase (no. M0247S; New England Biolabs, Inc) at 37°C for 20 min-
utes with continuous mixing in a thermal mixer. After adding the same volume of sonication
buffer (100 mM Tris-HCl, pH 8.1; 20 mM EDTA; 200 mMNaCl; 2% Triton X-100; 0.2%
sodium deoxycholate), lysates were sonicated for 15 minutes (30 seconds on, 30 seconds off)
using a Bioruptor Twin (model UCD-400; Diagenode Inc) and centrifuged at 21,130×g for 10
minutes. The cleared supernatant (equivalent to 10–20 mg of tissue) was incubated with 2 μg
rabbit polyclonal anti—histone H3 lysine 36 trimethylation (H3K36me3) antibody (no. 61101,
Active Motif Corp) on a rocker overnight. After adding 30 μL of protein G—agarose beads,
reactions were further incubated for 3 hours. Beads were extensively washed with ChIP buffer
(50 mM Tris-HCl, pH 8.1; 10 mM EDTA; 100 mMNaCl; 1% Triton X-100; 0.1% sodium deox-
ycholate), high-salt buffer (50 mM Tris-HCl, pH 8.1; 10 mM EDTA; 500 mMNaCl; 1% Triton
X-100; 0.1% sodium deoxycholate), LiCl2 buffer (10 mM Tris-HCl, pH 8.0; 0.25 M LiCl2; 0.5%
NP-40; 0.5% sodium deoxycholate; 1 mM EDTA), and Tris-EDTA buffer. Bound chromatin
was eluted and reverse—cross-linked at 65°C overnight. DNA was purified using a MinElute
PCR purification kit (no. 28004; Qiagen Inc) after RNase A and proteinase K treatment.
H3K36me3 chromatin immunoprecipitation was validated by performing quantitative PCR in
the genomic loci targeting the ACTB gene body (positive control) and the neighboring inter-
genic region (negative control). ChIP quantitative PCR was carried out in triplicate on indi-
cated genomic regions using SYBR Green Supermix (Bio-Rad Laboratories, Inc). The following
primer sequences were used: hActin: F 50-CCTCATGGCCTTGTCACAC; hActin: R 50-
GCCCTTTCTCACTGGTTCTCT; hCh19-intergenic: F 50-AGCTTGTCTTTCCCAAGTTTACTC;
hCh19-intergenic: R 50-TAGCTGTCGCACTTCAGAGGA. The comparative ΔCtmethod was
used to determine relative enrichment compared with input.
ChIP-seq libraries were then prepared from 10 ng ChIP and input DNA using the Ovation
Ultralow DRMultiplex kit (NuGEN Technologies Inc). ChIP-seq libraries were sequenced to
51 base pairs (bp) from both ends on an Illumina HiSeq 2000 instrument.
Multidisciplinary Renal Cell Carcinomas Biobank
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Sequence data were analyzed by the Mayo Clinic Center for Individualized Medicine Bioin-
formatics Program. The ChIP-Seq pipeline version 2 integrates open-source software packages
to analyze ChIP sequencing data and identify profiles from chromatin regulators, posttransla-
tional histone modifications, and transcription factor binding [13]. The source code is publicly
available at http://bioinformaticstools.mayo.edu/research/hichipseq-pipeline/, with hyperlinks
corresponding to individual software packages. The main features include 1) read-quality
checking; 2) read mapping and filtering; 3) library quality assessment; 4) peak calling analysis;
and 5) data visualization (S1 Fig). FastQC (http://www.bioinformatics.babraham.ac.uk/
projects/fastqc/) (publicly available software) was used to assess the 51-bp paired-end reads for
the average quality score per base position. The Burrows-Wheeler Alignment tool (http://bio-
bwa.sourceforge.net/) (publicly available software) was used to map the paired-end reads to the
reference genome (hg19) [14]. SICER, a package developed for scoring broad binding events
(http://home.gwu.edu/~wpeng/Software.htm) (publicly available software), was used to iden-
tify H3K36me3 peaks [15]. To plot the genome-wide enrichment, we split the human genome
into nonoverlapping 500-bp windows, estimated the number of mapped fragments overlap-
ping each window, and normalized to the number of fragments per 10 million mapped pairs.
To profile the level of H3K36me3 occupancy within the gene-body, we downloaded the
RefGene annotation from the UCSC Genome Browser table browser (http://genome.ucsc.edu/
cgi-bin/hgTables) and intersected that with peak coordinates using BEDTools (http://bedtools.
readthedocs.org/en/latest/#) (publicly available) [16].
RNA Sequencing of Frozen Nephrectomy Specimens
Frozen nephrectomy tissue samples (25–30 mg) were pulverized using a hammer and placed in
lysis reagent (Qiazol, no. 79306; Qiagen Inc). RNA from the pulverized tissue was isolated
using the miRNeasy Mini Kit (no. 217004; Qiagen Inc) on the QIAcube instrument (no.
9001292; Qiagen Inc). RNA libraries were prepared according to the manufacturer’s instruc-
tions for the Encore NGS Library Systems (NuGEN Technologies Inc). Briefly, first-strand
cDNA was generated from total RNA using DNA/RNA chimeric primers and reverse tran-
scriptase, creating a cDNA/RNA hybrid. The second-strand cDNA was then synthesized from
the DNA/RNA duplex. The resulting double-stranded cDNA was amplified by Single Primer
Isothermal Amplification (NuGEN Technologies Inc) using a chimeric primer, DNA polymer-
ase, and RNase H. After amplification, products were modified by random priming and exten-
sion to create double-stranded products that were suitable for generating libraries for
sequencing. The double-stranded products (200 ng) were fragmented in an ultrasonicator
(E210; Covaris Inc) for 5 minutes to generate ~150-bp fragments, which then underwent
blunt-end repair. Illumina-compatible paired-end index adapters were ligated to the 50 and 30
ends of each fragment. The adapter-modified cDNA fragments were enriched with 5 cycles of
PCR amplification. The concentration and size distribution of the resulting libraries were
determined by using a Bioanalyzer DNA 1000 chip (Agilent Technologies, Inc). The concentra-
tion values were confirmed by Qubit fluorometry (Life Technologies Corp). Libraries were
loaded onto Illumina TruSeq v3 paired-end flow cells at concentrations of 8–10 pM to generate
cluster densities of 600,000–800,000/mm2 following Illumina’s standard protocol and using the
Illumina cBot and paired-end cluster kit version 3. Flow cells were sequenced as 100×2 paired-
end reads on an Illumina HiSeq 2000 using TruSeq SBS sequencing kit version 3 and HiSeq
Control (version 2.0.12.0; Illumina, Inc [commercial software]). Base-calling was performed
using Real-Time (version 1.17.21.3; Illumina, Inc [commercial analysis software]).
After proper permissions were obtained, RNA sequencing data on normal and tumor kid-
ney samples were downloaded from TCGA kidney cancer (https://tcga-data.nci.nih.gov/tcga/);
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Kidney Renal Cell Carcinoma [KIRC] dataset. Sequencing data have been submitted to Gene
Expression Omnibus, accession number GSE69198. For meta-analyses, we first normalized
reads per kilobase of transcript per million reads mapped (RPKM) values from our frozen-tis-
sue RNA sequencing data, with the standard normalization method of TCGA, ie, RPKM
75th percentile RPKM value × 1,000.
Results
Biobanking Work Flow and Pathologic Characteristics of the RCC
Biobank Specimens
Patients undergoing evaluation for genitourinary diseases were recruited and provided consent
during urology, radiation oncology, pathology, or medical oncology appointments. Pathologic
characteristics of the cohort enrolled from June 1, 2010, to January 1, 2013, are summarized in
Table 1. The biobank represents earlier T stages of RCC, consistent with surgical treatments for
localized disease. Fig 1 illustrates the work flow for consent of patients, collection and process-
ing of biospecimens, and data input into the centralized REDCap database. To accommodate
tissues from diverse anatomical sites, we developed a generalized work flow for collection of
frozen tissue, blood, and urine. For tissue, the priority is for diagnostic testing for purposes of
routine clinical care, with the rest of the tissue frozen at −80°C in a manner compatible with
TCGA tissue collection requirements [17,18]. The protocol is compatible with collection of tis-
sue at the time of surgical resection or biopsy at the primary site (nephrectomy) and at distant
metastatic sites.
Table 1. Clinicopathologic Characteristics of Renal Cell Carcinoma Specimens Collected in the Multi-
disciplinary Genitourinary Diseases Biospecimen Bank at Mayo Clinic, Scottsdale, Arizona (N = 328).
Characteristic Value
Age, median (range), y 66 (32–92)
Sex, No. (%)
Male 115 (35)
Female 213 (65)
Cancer T stage, No. (%)
T1a 176 (54)
T1b 67 (20)
T2a 15 (5)
T2b 7 (2)
T3a 40 (12)
T3b 13 (4)
T3c 3 (1)
T4 7 (2)
Pathology, No. (%)
Clear cell 216 (66)
Papillary 36 (11)
Oncocytoma 36 (11)
Chromophobe 20 (6)
Angiomyolipoma 13 (4)
Othera 7 (2)
a Includes unclassified, mucinous, and tubular spindle cell carcinoma.
doi:10.1371/journal.pone.0132831.t001
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TCGA Specimen Submission and Quality Control
Frozen papillary RCC samples were submitted for processing to TCGA. As a control, buffy
coat collected concomitant with tissue was submitted as a germline control. The genitourinary
pathologist reviewed the diagnostic slide, which is a mirror image of the frozen tissue and
FFPE, to ensure that samples met tumor-specific pathology requirements. The mean (SD)
tumor weight was 376 (130) mg. DNA and RNA yields from tumor and matched buffy coat are
listed in Table 2. Representative diagnostic slides were sent to TCGA (Fig 2). All extracted
DNA samples passed the TCGA requirements. With our work flow, 2 of 16 submitted tumors
(12.5%) did not meet RNA integrity number (RIN) requirements (RIN<7). Our mean (SD)
TCGA RINs were 8.1 (0.8) for papillary RCC. Table 3 lists the genomic platforms used to ana-
lyze TCGA samples with publicly accessible data.
Analysis of Albumin and apoA-I Oxidation as a Metric of Plasma
Specimen Integrity
As previously reported [12], albumin and apoA-I in human blood plasma are susceptible to
oxidative S-cysteinylation and methionine sulfoxidation, respectively, when plasma is exposed
Fig 1. Multidisciplinary Genitourinary Diseases Biospecimen BankWork Flow. Left, Standard operating procedures involved obtaining patient consent,
prospective specimen processing, clinical data collection, and scheduling of future collections associated with standard-of-care blood draws. Right, The
pathology work flow for banking frozen tissue. (Data from Pena-Llopis S, Brugarolas J. Simultaneous isolation of high-quality DNA, RNA, miRNA and
proteins from tissues for genomic applications. Nat Protoc. 2013 Nov;8[11]:2240–55. Epub 2013 Oct 17.) A portion of the tissue is frozen (A) and the rest is
embedded in paraffin (C). A standardized cube of tissue (B) is cut and frozen for future genomic analyses, with parallel mirror slides representing (A) and (C)
for assessment of cellularity as an addendum in the pathology synoptic report. Either slide is sent for independent pathology review to the Biospecimen Core
Resource of The Cancer Genome Atlas. FFPE, indicates formalin-fixed, paraffin-embedded; lab, laboratory; preop, preoperative; REDCap, Research
Electronic Data Capture; RLIMS, Research and Laboratory Information Management System.
doi:10.1371/journal.pone.0132831.g001
Table 2. DNA and RNA Yields From Samples Submitted to The Cancer Genome Atlas.
Sample a Yield, mean (SD), μg
Tumor DNA 28.6 (14.9)
Buffy coat DNA 48.0 (22.4)
Tumor RNA 46.9 (10.3)
a The mean (SD) tumor weight was 376 (130) mg.
doi:10.1371/journal.pone.0132831.t002
Multidisciplinary Renal Cell Carcinomas Biobank
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to temperatures above its freezing point of −30°C. At both room temperature and −20°C, albu-
min oxidation (S-cysteinylation) increases as per the complement of an exponential decay
function before reaching a plateau (for most samples) at a relative fractional abundance of
about 0.4. ApoA-I methionine oxidation proceeds at a slower pace, requiring days of exposure
to room temperature or months of storage at −20°C [12]. On average, the banked samples
from patients with RCC described in this study had albumin oxidation (S-cysteinylation) levels
consistent with several hours’ exposure to room temperature and no long-term storage above
Fig 2. Papillary Renal Cell Carcinoma (RCC) Samples Submitted to The Cancer Genome Atlas (TCGA). A, Representative mirror images of top slides
sent for independent pathology review to the Biospecimen Core Resource of TCGA. H&E indicates hematoxylin-eosin stain; original magnification ×10 (left)
and ×40 (right). B, Scatterplot of TCGA quality assessment of RNA processed from papillary RCC specimens. The black horizontal dotted line represents the
mean, with the vertical error bars representing the SD. RNA integrity numbers (RINs) were assessed by TCGA RNA bioanalyzer. Two samples with RIN <7
were disqualified.
doi:10.1371/journal.pone.0132831.g002
Multidisciplinary Renal Cell Carcinomas Biobank
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−30°C (Fig 3). Consistent with this observation, apoA-I oxidation remained below quantifiable
levels for tested samples.
H3K36me3 Profiling by ChIP Sequencing
We tested the utility of our banked specimens for emerging technologies such as ChIP sequenc-
ing that require larger amounts of frozen tissue (>100 mg). Altered chromatin accessibility is
observed in clear cell RCC and is associated with alterations of H3K36me3 [19–22]. Compared
to other genome-wide discovery platforms, ChIP sequencing often requires larger amounts of
tissue (>100 mg). To determine whether our biobanking work flow for specimens was compat-
ible with H3K36me3 ChIP sequencing, we performed ChIP quantitative polymerase chain
reaction to ensure quality and yield of immunoprecipitated chromatin from 6 samples. An
H3K36me3 antibody was used for immunoprecipitation of endogenous H3K36me3-bound
DNA. Since H3K36me3 is enriched at exons and active genes, polymerase chain reaction prim-
ers were optimized for active genes, such as actin, and for an intergenic region (negative con-
trol) [23,24]. At a minimum, 4-fold enrichment is required before proceeding to sequencing
[25,26]. We found that actin was enriched 8- to 32-fold over the intergenic controls (Fig 4),
which indicated that the quality and yield of immunoprecipitated DNA/chromatin complexes
were sufficient for generating ChIP-sequencing libraries. S2 Fig shows the optimal 100–400 bp
DNA fragments that were compatible with ChIP sequencing.
To evaluate the properties of ChIP-sequencing libraries derived from banked frozen
nephrectomy samples, we checked paired-end read quality, genome-wide enrichment level,
and distribution of H3K36me3 occupancy. Both reads had good quality, with FastQC scores of
32 to 39 across all 51 bp (Fig 5A and 5B). The first 3 bp had the lowest quality score for both
reads, with the first read having slightly better sequencing quality, as is typically seen for
paired-end sequencing. In addition, over 95% of the first reads had an average quality score of
30 compared to 91% to 92% of the second reads. Only a small proportion of the reads had
poor quality scores (20, on average):<0.5% for the first read and<3% for the second,
Table 3. Papillary Renal Cell Carcinoma SamplesWith Available Genomic Data from The Cancer Genome Atlas Data Portala.
TCGA ID Clinical Information DNA Methylation SNP Array MicroRNA Sequencing RPPA RNA Sequencing
TCGA-SX-A7SL ✓ ✓ ✓ ✓ ✓
TCGA-SX-A7SM ✓ ✓ ✓ ✓ ✓ ✓
TCGA-SX-A7SN ✓ ✓ ✓ ✓ ✓ ✓
TCGA-SX-A7SO ✓ ✓ ✓ ✓ ✓ ✓
TCGA-SX-A7SP ✓ ✓ ✓ ✓ ✓ ✓
TCGA-SX-A7SQ ✓ ✓ ✓ ✓ ✓ ✓
TCGA-SX-A7SR ✓ ✓
TCGA-SX-A7SS ✓ ✓ ✓ ✓ ✓ ✓
TCGA-SX-A7SU ✓ ✓ ✓ ✓ ✓
TCGA-SX-A71R ✓ ✓ ✓ ✓ ✓ ✓
TCGA-SX-A71S ✓ ✓ ✓ ✓ ✓
TCGA-SX-A71U ✓ ✓ ✓ ✓ ✓ ✓
TCGA-SX-A71V ✓ ✓ ✓ ✓ ✓
TCGA-SX-A71W ✓ ✓
Abbreviations: ID, identifier; RPPA, reverse phase protein array; SNP, single nucleotide polymorphism; TCGA, The Cancer Genome Atlas.
a Entries with checkmarks indicate availability as of 4/22/15 from TCGA Data Portal.
doi:10.1371/journal.pone.0132831.t003
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respectively (data not shown). Each library had 27.0 to 30.6 million pairs of raw reads, and
91.7% to 92.8% of the pairs mapped to the reference genome (hg19) by BWA. Of these, 85.4%
to 86.7% represented uniquely mapped pairs.
For ChIP-sequencing experiments, another quality measurement is the level of enrichment
between immunoprecipitated DNA and the input DNA control. The box plots represent the
top 5% of the 500-bp windows with the highest number of fragments (Fig 5C). The peak
regions from each H3K36me3 immunoprecipitated library showed an average of about 4-fold
enrichment over the corresponding regions in the input library. In published ChIP-sequencing
studies in cell lines, H3K36me3 is predominantly associated with gene bodies [23,27]. To map
H3K36me3 in gene bodies, we examined the distribution of H3K36me3 across each chromo-
some. The 3 RCC libraries showed a 2% to 5% reduction of H3K36me3 occupancy over the
gene body, compared to matched normal samples (Fig 5D). H3K36me3 is enriched at exons,
and the difference between different chromosomes in H3K36me3 occupancy over the gene
body largely reflected the ratio of exon sizes over gene sizes. For example, chromosome 19 had
the highest size ratio of exon/gene (13.6%) and also the highest H3K36me3 coverage of gene
body (47.4%-53.5%). Similar patterns were also found for chromosomes 16 and 22.
RNA Sequencing Quality of Frozen Nephrectomy Samples
To assess the quality of RNA sequencing data from frozen nephrectomy samples, we analyzed
RNA from frozen tissue profiled in parallel by ChIP sequencing (N = 6). A representative bioa-
nalyzer profile and RIN of isolated RNA from paired samples (tumor and normal) is depicted
in S3 Fig. We first examined the sequencing quality per base for forward and reverse reads. As
shown in S4 Fig, the average Phred score of each base in all reads was above 30, indicating a
high-quality sequencing run. Next, we compared the quality of RNA sequencing from our fro-
zen tissues with that of an RCC cell line (786-O), which was prepared under optimal RNA
Fig 3. Albumin Oxidation (S-Cysteinylation) Observed in the Banked Renal Cell Carcinoma (RCC)
Plasma Samples.Control plasma was freshly collected from a nominally healthy donor, and albumin
oxidation levels were observed at 25°C Significantly less albumin oxidation was observed in samples from
patients with RCC compared with albumin in plasma kept at 25°C for17.5 hours (P<.001; Mann-Whitney U
test). (Data from Borges CR et al [12].)
doi:10.1371/journal.pone.0132831.g003
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isolation conditions. After genome alignments, only 0.2%-0.4% of total reads from frozen tis-
sues failed the default quality check steps of Bowtie2 (disqualified reads are shown in Table 4),
which was comparable to the disqualification ratio (0.1%) of the 786-O cell line. The mapping
ratios for our frozen tissues were slightly lower (76.4%-83.8%) than those from the cell line
(84.5%).
One of the key metrics of RNA sequencing quality and coverage is the number of identified
genes. To identify genes expressed in both the Mayo Clinic and TCGA cohorts with high confi-
dence, we counted genes with normalized expression values128 that corresponded approxi-
mately to an average of 1.0 RPKM across all samples. As shown in Table 5, among ~20,500
protein-coding genes, we observed a similar number of expressed genes in the Mayo Clinic and
TCGA tissues. Poor-quality RNA sequencing often results in biased amplification and conse-
quent overrepresentation of a subset of genes. To assess the RNA sequencing quality, expres-
sion levels of the most abundant genes across all samples were examined. Fig 6A shows that
TPT1, EEF1A1, B2M, and GPX3 were most abundant in both the Mayo Clinic and TCGA sam-
ples. With the exception of TPT1 (highly abundant in the Mayo Clinic samples and accounted
for up to 9.5% of expression values of total normalized counts), we did not identify any other
Fig 4. Chromatin Immunoprecipitation Quantitative Polymerase Chain Reaction Analysis of Histone H3 Lysine 36 Trimethylation (H3K36me3).
H3K36me3 is enriched at the actin locus, but not in the intergenic region, in both tumor and uninvolved kidney. Error bars represent SD as determined from
duplicate experiments. ccRCC indicates clear cell renal cell carcinoma.
doi:10.1371/journal.pone.0132831.g004
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overrepresented genes. Despite fundamental differences in sample source, sample processing,
and sequencing library generation, the overall correlation coefficients between the Mayo Clinic
vs TCGA tissues ranged from 0.75 to 0.82 (Fig 6B). Although expression levels of low-abun-
dance genes were slightly overestimated in the Mayo Clinic samples, genes with mid to high
Fig 5. Quality Assessment of Chromatin Immunoprecipitation CoupledWith High-throughput Sequkencing. A, First end-read and, B, second end-
read average quality score per base pair (bp) position assessment using FastQC. Higher scores correspond to better base calls. C, Box plots of enrichment
of H3K36me3 immunoprecipitation (IP; red) over the matched control input library (Input; green). The human genome was split into 500-bp nonoverlapping
windows, and the number of mapped pairs per window was calculated using BEDTools and normalized to a library size of 10 million uniquely mapped reads.
The plots represent the top 5% of the 500-bp windows with the highe st counts in IP and the corresponding windows in input. D, Gene-body coverage by
H3K36me3-binding sites. H3K36me3-binding sites identified by SICER (Spatial Clustering for Identification of ChIP-Enriched Regions) were intersected with
gene coordinates to calculate the gene-body coverage (y-axis). On the x-axis, 1 to 22 represents chromosomes 1 to 22; 23 represents the X chromosome;
and 24 represents the Y chromosome. ccRCC1 indicates clear cell renal cell carcinoma 1; ccRCC2, clear cell renal cell carcinoma 2; ccRCC3, clear cell renal
cell carcinoma 3; Uninv., uninvolved.
doi:10.1371/journal.pone.0132831.g005
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abundance were more linearly aligned. These data support the compatibility of our biobanking
protocol with RNA and ChIP-sequencing platforms for frozen RCC.
Discussion
The Multidisciplinary Genitourinary Diseases Biospecimen Bank in Arizona is a collaboration
among investigators in urology, radiation oncology, pathology, and medical oncology to study
the spectrum of benign and malignant genitourinary disease. Our work flow suggests that our
biobanking protocol for RCC does not interfere with routine clinical care and is compatible
with systematic cancer genomics projects such as TCGA and MS analysis of plasma, as well as
with newer technologies (eg, ChIP sequencing) requiring larger quantities of frozen tissue.
Herein, we reported the quality control of our TCGA submissions for papillary RCC (paired
frozen tissue, mirror slide, and buffy coat), MS analysis of albumin S-cysteinylation as a surro-
gate of plasma integrity, and ChIP sequencing analysis of frozen tissues.
With matched temporal collections of frozen tissue and buffy coat, we can link molecular
characterizations of DNA, RNA, and protein to treatment outcomes. The annotation of tumor
cellularity of matched FFPE specimens in the pathology report expedites the identification of
tumor blocks suitable for targeted exome sequencing, and immunohistochemistry [28–30].
Integration of the clinical information into a REDCap database facilitates collaborations to
query specific disease cohorts linked to outcomes data.
Table 4. Comparison of Mapped Reads Between Frozen Nephrectomy Samples and a Renal Cell Carcinoma Cell Line (786-O).
Source and Sample ID Total Reads Disqualified Reads Unmapped Reads Mapped Reads
Count % Total Count % Total Count % Total
Kidney tumor
ccRCC1 414,293,024 1,801,533 0.4 79,723,359 19.2 332,768,132 80.3
Uninv kidney 1 421,101,208 1,018,419 0.2 68,354,681 16.2 351,728,108 83.5
ccRCC2 427,575,250 1,535,886 0.4 99,270,525 23.2 326,768,839 76.4
Uninv kidney 2 426,317,444 1,205,535 0.3 67,952,300 15.9 357,159,609 83.8
ccRCC3 409,282,398 1,565,821 0.4 92,300,799 22.6 315,415,778 77.1
Uninv kidney 3 424,633,572 878,592 0.2 75,578,922 17.8 348,176,058 82.0
Cell line
786-O 164,760,980 149,964 0.1 25,449,107 15.4 139,161,909 84.5
Abbreviations: ccRCC1, clear cell renal cell carcinoma 1; ccRCC2, clear cell renal cell carcinoma 2; ccRCC3, clear cell renal cell carcinoma 3; Uninv,
uninvolved.
doi:10.1371/journal.pone.0132831.t004
Table 5. Comparison of Mapped Reads Between the Mayo Clinic and TCGA Nephrectomy Samples.
Sample Group No. of Samples No. of Genes With Normalized Score 128, Mean (SD)
Mayo kidney tumor 6 12,177.0 (317.2)
TCGA kidney tumor 533 11,339.8 (324.8)
TCGA normal kidney 72 11,444.5 (172.9)
Abbreviation: TCGA, The Cancer Genome Atlas.
doi:10.1371/journal.pone.0132831.t005
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Fig 6. Expression Profiles and Correlation of Genes in the Mayo Clinic and TCGACohorts. A, Expression of the most abundant genes in Mayo Clinic
tissues. Expression levels of the 30 most-abundant genes in frozen tumors (upper 6 bars) and TCGA kidney tumors (averaged from 553 samples) are shown
in stacked bars, with percentages of total normalized counts. Reads for TPT1 occupied up to 9.5% of total reads. B, Correlation of gene expression between
the Mayo Clinic and TCGA kidney tumors. Normalized expression values of a representative Mayo Clinic tumor and TCGA kidney tumor samples (averaged
from 553 samples) were compared. Genes in the boxed area have normalized expression values128. ccRCC1 indicates clear cell renal cell carcinoma 1;
ccRCC2, clear cell renal cell carcinoma 2; ccRCC3, clear cell renal cell carcinoma 3; TCGA, The Cancer Genome Atlas; Uninv, uninvolved.
doi:10.1371/journal.pone.0132831.g006
Multidisciplinary Renal Cell Carcinomas Biobank
PLOS ONE | DOI:10.1371/journal.pone.0132831 July 16, 2015 15 / 20
Limitations
Our study has several limitations. First, our study represents biospecimens processed within 4
years of collection. The biobank started prospective collections in 2010, and our DNA and
RNA yields, MS analysis, and ChIP sequencing may not be representative of samples stored
longer than 4 years or of other genitourinary tumors (eg, urothelial, testicular, penile, or pros-
tate cancers). For ChIP sequencing, we chose a covalent histone modification, H3K36me3, for
enrichment of DNA; our H3K36me3 ChIP enrichment may not be comparable to ChIP enrich-
ment using antibodies directed to transcription factors, which may not be as stable in banked
frozen tissue. Our RNA yields reflect an overall mean warm-ischemia time of 45.8 minutes
(range, 10–110 minutes) for the RCC specimens (N = 328), which was influenced by factors
such as partial vs radical nephrectomy or an open vs a minimally invasive approach. Despite
the warm-ischemia time, the overall rate of sample disqualification for RIN<7 for TCGA sub-
missions was 12.5%. In a prior study, RNA degradation in nephrectomy specimens was
observed primarily after 4 hours at 37°C, and prolonged warm ischemia was associated with
changes in gene expression profiles [31]. Furthermore, we studied only nephrectomy speci-
mens; other tissues may have different sensitivities to warm-ischemia times.
Second, we examined the compatibility only of frozen nephrectomy specimens, rather than
archival FFPE nephrectomy specimens, with various discovery platforms. The use of FFPE has
additional challenges that include fragmentation and degradation of nucleic acids, and alter-
ations of epitopes during the fixation and deparaffinization process. FFPE-compatible DNA,
RNA, and ChIP sequencing protocols for various tissues have been published, but further
study is required to determine the compatibility of these protocols with FFPE nephrectomy tis-
sue [32–34].
Third, elevated concentrations of circulating free cysteine and cystine (the disulfide dimer
of free cysteine) have been reported in patients with severely compromised renal function [35].
Their effects on albumin S-cysteinylation in vivo are not entirely clear because the ratio of cys-
teine to cystine in blood does not vary much [36], presumably because the redox potential of
blood plasma is rather tightly regulated. Ex vivo, however, elevated concentrations of cysteine
and cystine in the presence of oxygen would almost certainly lead to higher-than-normal maxi-
mum levels of S-cysteinylated albumin through disulfide exchange with cystine and through
sulfenic acid—mediated disulfide bond formation with cysteine [37–40]. In some patients with
renal failure, the fractional abundance of S-cysteinylated albumin has been reported at over
50%, although these studies lacked detailed documentation of sample-handling conditions
[41–44]. Essentially, this means that elevated ex vivo levels of albumin S-cysteinylation are
likely to occur faster in patients with renal failure than in patients without elevated plasma
cysteine or cystine.
Conclusion
Genitourinary diseases represent a spectrum of disease with varying phenotypes and geno-
types. The increase in tumor molecular profiling has led to a need for integration of genotype-
phenotype relationships with contemporary treatments (definitive surgical management, med-
ical therapy, and/or radiation). The construction of a biobank that encompasses both benign
and malignant genitourinary diseases may also elucidate the mechanism of the molecular pro-
gression of disease prior to overt clinical symptoms. Our multidisciplinary collaboration
ensures longitudinal collection of matched tissue, blood, and urine during the course of stan-
dard care as well as during experimental treatments that will be available for projects that
require access to pre- and/or postintervention time points. The prospective collection of frozen
biospecimens allows future next-generation platforms to interrogate specimens linked to
Multidisciplinary Renal Cell Carcinomas Biobank
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outcomes. A comprehensive prospective collection also facilitates banking of frozen tumors
with rare subtypes and histologies, which may not be identified until completion of dedicated
immunohistochemical staining (ie, not intraoperatively). Furthermore, the comparison of
benign and malignant tissue may yield clues regarding risk-based algorithms for personalized
treatment. The elucidation of distinct molecular phenotypes of RCC will further improve upon
the prognostic and therapeutic stratification of patients.
Supporting Information
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